CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
| Operating expenses: |
|
|
|
| Research and development |
$ 51,769
|
$ 21,226
|
$ 8,403
|
| General and administrative |
39,894
|
22,038
|
2,449
|
| Total operating expenses |
91,663
|
43,264
|
10,852
|
| Loss from operations |
(91,663)
|
(43,264)
|
(10,852)
|
| Other income (expense): |
|
|
|
| Change in fair value of preferred stock warrant liability |
(2,187)
|
(785)
|
1
|
| Interest expense |
(464)
|
(309)
|
(149)
|
| Interest income and other income (expense), net |
5,119
|
511
|
(16)
|
| Total other income (expense), net |
2,468
|
(583)
|
(164)
|
| Net loss |
(89,195)
|
(43,847)
|
(11,016)
|
| Accretion of Series A redeemable convertible preferred stock to redemption value |
|
(656)
|
(748)
|
| Net loss attributable to common stockholders |
$ (89,195)
|
$ (44,503)
|
$ (11,764)
|
| Net loss per share attributable to common stockholders, basic and diluted |
$ (2.27)
|
$ (5.55)
|
$ (1.63)
|
| Weighted average common shares outstanding, basic and diluted |
39,285,468
|
8,023,785
|
7,200,581
|
| Comprehensive loss: |
|
|
|
| Net loss |
$ (89,195)
|
$ (43,847)
|
$ (11,016)
|
| Other comprehensive loss: |
|
|
|
| Unrealized losses on investments, net of tax of $0 |
(29)
|
|
|
| Comprehensive loss |
$ (89,224)
|
$ (43,847)
|
$ (11,016)
|